Introduction
The Interferon Regulatory Factors (IRFs) are a family of transcription factors consisting of nine members (IRF-1, IRF-2, IRF-3, ISGF3g/p48, ICSBP, Pip/ ICSAT/IRF-4, IRF-5, IRF-6 and IRF-7) and virally encoded forms (vIRFs). All members of this family share signi®cant homology in the N-terminal 115 amino acids which comprise the DNA binding domain; for the IRF-3, IRF-4, IRF-5, ISGF3g and ICSBP proteins, the homology extends into the Cterminal IRF association domain with which these IRFs interact with other proteins or family members. IRFs can be classi®ed as transcriptional activators (IRF-1, IRF-3, IRF-7 and ISGF3g), repressors (IRF-2, ICSBP, and vIRF) or both (IRF-4). Studies characterizing IRF-expressing cell lines and IRF knockout mice reveal that each member of the IRF family exerts distinct roles in biological processes such as pathogen response, cytokine signaling, cell growth regulation and hematopoietic dierentiation (reviewed in Nguyen et al., 1997a) .
IRF-1 and IRF-2 are by far the best characterized members of the IRF family of transcription factors (reviewed in Nguyen et al., 1997a; Taniguchi et al., 1997) . These IRFs bind to similar DNA binding motifs, T / C -3') present in the promoters of many IFN and/or virusinducible genes. Structurally, the IRF-1 and IRF-2 proteins are similar, sharing 76% identity in the ®rst 154 N-terminal aa and 8% identity at the C-terminal end (Harada et al., 1989) , but possess very dierent activities Miyamoto et al., 1988; Harada et al., 1989; Reis et al., 1992) . IRF-1 serves as a transcriptional activator, whereas IRF-2 acts as an antagonistic transcriptional repressor. The functional dierences between IRF-1 and IRF-2 extend further to include an important role in cellular growth regulation; IRF-1 and IRF-2 tumor suppressor and oncogenic activity were demonstrated by IRF-2 induction of cellular transformation in NIH3T3 cells and tumor formation in nude mice, and reversal of the IRF-2-mediated tumorigenicity by IRF-1 (Harada et al., 1993) .
Studies performed with knockout mice illustrate that IRF-1 plays key roles in the regulation of various immune processes. Mice de®cient in the IRF-1 gene, while having normal numbers of immature CD4 7 CD8 + and CD4 + CD8
7 thymocytes, are 90% de®cient in mature CD8
+ T-cells in the thymus (Matsuyama et al., 1993) , suggesting impairment of CD8 + cell maturation in the IRF-1 knockout mice. This phenotype may be explained by the fact that IRF-1 upregulates expression of TAP1 and LMP2, genes which are important for positive selection of CD8 + cells . Furthermore, immune cells from IRF-1 7/7 mice exhibit defective Th1 responses ± impaired macrophage production of IL-12, de®cient CD4 + T-cell response to IL-12, ablated natural killer (NK) cell development, and exclusive Th2 dierentiation of macrophages and CD4 + T-cells in vitro (Taki et al., 1997) , implicating IRF-1 multiple stages of Th1 dierentiation. IRF-1 is also essential for the induction of NK cell-mediated cytotoxicity in vivo, since cytolytic activity of IRF-1
NK cells is defective, even following induction by virus infection, double-stranded RNA (dsRNA), IFN-b, IL-2 and IL-12 (Duncan et al., 1996) . Finally, IRF-1 exhibits an important function in the establishment of the antiviral state. Inhibition of encephalomyocarditis virus replication by type I and II IFN is dramatically impaired in IRF-1 7/7 mice. Furthermore, induction of the inducible iNOS, guanylate-binding protein (GBP) and 2'5'oligoadenylate synthetase (OAS) genes by IFNg is severely impaired in IRF-1 7/7 MEFs (Reis et al., 1994; Kimura et al., 1994) .
In a recent study, IRF-1 expressing cell lines were generated with the tetracycline-inducible expression system. Using these cell models, it was demonstrated that inducible IRF-1, IRF-1/RelA and IRF-2/RelA expression correlated with antiproliferative activity and upregulation of several growth regulatory genes (Nguyen et al., 1997b) . Since they exhibited similar eects, the use of the IRF/RelA fusion genes serve as useful tools to examine IRF-1 mediated activities. In this study, the IRF-1 and IRF-1/RelA cell lines and the method of dierential display/RNA ®ngerprinting were exploited to search for novel gene targets of IRF-1. As a result, secretory leukocyte protease inhibitor (SLPI) was identi®ed as a gene downregulated by IRF-1. Belonging to the family of a-1 antitrypsin antiproteinases, SLPI plays a primary role in the regulation of neutrophil-mediated in¯ammation through proteolysis and subsequent inhibition of the serine leukocyte proteases (Thompson and Ohlsson, 1986) . SLPI is also a regulator of the LPS response; although activated by LPS in wild-type macrophages and neutrophils, SLPI antagonizes the LPS response when overexpressed in macrophages (Jin et al., 1997) . Preliminary characterization of the role of IRF-1 in SLPI expression discloses a major IRF-1 binding site at the 7221 to 7200 SLPI promoter region and reveals complex regulation of SLPI expression involving both activation and repression by IRF-1. The identi®cation of SLPI as a target of IRF-1 regulation attributes a unique repressor function to IRF-1 and assigns a novel role for IRF-1 in the in¯ammatory process.
Results

RNA ®ngerprinting of cell lines inducibly expressing IRF-1/RelA
To identify genes regulated by IRF-1, RNA ®ngerprinting was performed on the recently characterized tetracycline-inducible control rtTA, rtTA-IRF-1 and rtTA-IRF-1/RelA expressing NIH3T3 cells (Nguyen et al., 1997b) . IRF-1/RelA is a chimeric protein consisting of the N-terminal DNA-binding domain of IRF-1 fused to the C-terminal transactivation domain of the RelA subunit of the NF-kB family of transcription factors . Structural similarity to IRF-1 led to the prediction and subsequent con®rmation that IRF-1/RelA was able to mimic IRF-1 as a transactivator and tumor suppressor (Nguyen et al., 1997b) , making this transgene a complementary tool to investigate IRF-1-mediated activities. rtTA-IRF-1/RelA cells were used preferentially for RNA ®ngerprinting due to their low uninduced transgene levels and high inducibility of expression (Nguyen et al., 1997b ).
An RNA ®ngerprint resulting from cDNA amplification using three dierent primer sets is presented in Figure 1 . A prominent 400 base pair (bp) band ampli®ed from primer set 1 in undiluted and 100-fold diluted cDNA from 72 h Dox-induced control rtTA cells (Figure 1, lanes 1 and 2) was absent in cDNA from 72 h Dox-induced IRF-1/RelA cells (Figure 1 , lanes 3 and 4). Primer sets 2 and 3 generated many distinct bands by RNA ®ngerprinting but none were dierentially expressed (Figure 1 , lanes 5 ± 12). The 400 bp band was isolated, subcloned and sequenced, and the resulting sequence was 100% homologous to a fragment of the murine secretory leukocyte protease inhibitor (SLPI) gene.
The 400 bp fragment was used as a probe for Northern blot to analyse SLPI expression following induction of IRF-1 and IRF/RelA at varying times following Dox induction. Figure 2 illustrates the kinetics of expression of SLPI mRNA following induction of IRF-1/RelA. Uninduced cells exhibited detectable endogenous levels of SLPI. Interestingly, following Dox induction of IRF-1/RelA, two distinct patterns of SLPI mRNA expression were observed. Two hours after Dox treatment (Figure 2 , lane 2), SLPI levels increased, attaining ®vefold higher levels by 4 h after Dox induction, when IRF-1/RelA mRNA levels were detected (Figure 2 , lane 3). However, 12 ± 48 h following Dox induction, SLPI mRNA levels decreased to undetectable levels ( Figure 2 , lanes 4 ± 10). Similar kinetics of SLPI expression were observed upon Dox induction of rtTA-IRF-1 cells (data not shown). Several experiments con®rm that the increase in SLPI expression observed early in induction is not due to the eects of doxycycline itself (Nguyen et al., 1997b) . From these results, SLPI is a gene which is dually regulated by IRF-1 in a dose-dependent manner: SLPI expression appears to be activated early after Dox induction of IRF-1/RelA when transgene concentrations are low, and later suppressed when peak, relatively high levels of IRF-1/RelA are attained. (Nguyen et al., 1997b) . Thus, dsRNA is a strong activator of SLPI expression, and dsRNA-mediated induction of SLPI expression is suppressed by induced IRF-1 or IRF-1/ RelA expression.
Detection of IRF-1 binding activity at two regions of the SLPI promoter
To characterize the role of IRF-1 in the regulation of SLPI expression, the available human SLPI promoter was analysed for transcription factor consensus sites. The sequence of the SLPI promoter is shown in Figure  4 . Initially, one ISRE-like and two NF-kB-like sites were detected in the 789 to 745 region, and two oligonucleotides were tested for binding by EMSA. BS1 (nt 789 to 761) encompassed the upstream NFkB-like site and the ISRE-like site, while BS2 (nt 779 to 745) contained the same ISRE-like site and the downstream NF-kB-like site. EMSA analysis showed that polyhistidine-tagged recombinant IRF-1 or IRF-2 protein did not bind to either BS1 nor BS2 (data not shown).
Figure 1 RNA ®ngerprint of rtTA and rtTA-IRF-1/RelA cells. Total RNA (2 mg) from 72 h Dox-induced rtTA (lanes 1, 2, 5, 6, 9, and 10) or rtTA-IRF-1/RelA (lanes 3, 4, 7, 8, 11 and 12) cells was used for RNA ®ngerprinting reactions using three dierent primer sets. To ensure reproducibility, PCR reactions were also performed on 1 : 100 dilutions of the cDNA product from each cell sample. The 400 bp band which corresponds to SLPI is identi®ed Figure 2 Expression of SLPI mRNA in rtTA-IRF-1/RelA cells. Twenty mg of total RNA prepared from rtTA-IRF-1/RelA cells 0 ± 96 h following Dox induction was used for Northern blot analysis with the 400 bp SLPI DNA fragment isolated from the RNA ®ngerprint or a 5' 300 bp IRF-1 DNA fragment as a probe. As a control of RNA loading, 28S RNA obtained from migration of total RNA on the agarose gel used for Northern blot analysis is presented
To examine the SLPI promoter sequence for IRF-1 binding sites, EMSAs were performed with recombinant IRF-1 protein using the entire promoter sequence as a probe (Figure 5a ). Interestingly, IRF-1 bound to the promoter sequence ( Figure 5a , lane 1). To isolate the region to which IRF-1 may bind, the promoter was digested with the EcoRI restriction enzyme into two fragments: SLPI-H/E (the 5' 207 nt region; nt 7276 to 769) and SLPI-E/A (the remaining 3' 69 nt region; nt 769 to +1), which includes 9 nt of the BS1 and the entire BS2 sequence. Strikingly, IRF-1 bound to both fragments of the promoter (Figure 5a , lanes 3 and 5). The speci®city of the IRF-1 DNA binding complex was con®rmed by supershift analysis using an IRF-1 speci®c antibody (Figure 5a , lanes 2, 4 and 6). No IRF-1 DNA binding activity was detected on BS12, a probe consisting of BS1 and BS2 together (789 to 745 nt), and the weak band observed was not shifted in the presence of IRF-1 antibody (Figure 5a , lanes 7 and 8). IRF-2 did not bind to the SLPI promoter despite the fact that it recognizes a similar DNA binding motif as IRF-1 . These results demonstrate the presence of at least two IRF-1 binding sites in the SLPI promoter: one site is located in the upstream 7200 region, and the other site is located within the proximal 745 region, adjacent to the TATA box.
To further delineate the IRF-1 site in the SLPI 57 promoter, in vitro footprinting was performed using recombinant IRF-1 protein and a 5'-radiolabeled SLPI promoter sequence as a probe. A representative DNase I footprint is presented in Figure 5b . SLPI promoter DNA in the absence of IRF-1 protein displayed a characteristic DNase I pattern compared to the control DNA ladder (Figure 5b , lanes 1 and 2). In the presence of increasing amounts of IRF-1 protein, a region between nt 7221 and 7200 was protected from DNase I treatment (Figure 5b , lanes 5 and 6). The protected sequence is rich in cytosine (C) and thymidine (T) bases, consistent with the 5'-GAAA-3' stretches found in the IRF-1 consensus sequence.
To con®rm binding of IRF-1 to the region between nt 7221 and 7200, an oligonucleotide representing the SLPI promoter sequence between nt 7224 and 7201 (F1A) was synthesized and tested for binding by EMSA. As shown in Figure 5c , recombinant IRF-1 protein bound to F1A, as addition of increasing amounts of IRF-1 resulted in increased F1A DNA binding activity (Figure 5c, lanes 1 to 3) . The speci®city of the IRF-1 DNA binding complex was con®rmed by supershift analysis using an IRF-1 speci®c antibody ( Figure 5c , lane 4). As predicted, F1A did not bind recombinant IRF-2 protein (Figure 5c , lanes 5 ± 7). Three thymidine residues at nt 7211 to 7209 are important for IRF-1 binding to F1A, since no IRF binding was detected on DF1A, an F1A oligonucleotide in which the three thymidine residues at nt 7211 to 7209 were substituted for adenines ( Figure 5c , lanes 8 ± 10). Whole cell extracts from 7 h and 48 h Doxinduced IRF-1/RelA cells also bound to F1A (data not shown). These observations demonstrate the existence of an IRF-1 binding site situated between nt 7221 and 7200 of the SLPI promoter. Since the only other potential ISRE-site in the SLPI-H/E promoter fragment (nt 7276 to 769) between 774 and 765 did not bind IRF-1 (Figure 5a , lanes 7 and 8), F1A likely accounts for the DNA binding activity observed in the SLPI-H/E region.
IRF-1 protein also bound to a second site on the SLPI promoter, as shown by IRF-1 binding to SLPI-E/ A (Figure 5a , lanes 5 and 6); analysis of the SLPI-E/A sequence revealed a 5'-GAAA-3' sequence at nt 742 to 739. The F1B oligonucleotide which encompasses this 5'-GAAA-3' sequence was found to be bound by IRF-1 with about tenfold lower anity than F1A (data not shown), suggesting the existence of a second, putative Cha and Deisseroth, 1994) . To test the possibility that SLPI expression may be suppressed directly by IRF-1 induced IRF-2, the kinetics of IRF-2 expression was examined in Dox-induced IRF-1/RelA cells ( Figure 6 ). As shown in Figure 6a , IRF-2 protein levels did not change signi®cantly following Dox induction of IRF-1/ Figure 5 Detection of IRF-1 DNA binding to two regions of the SLPI promoter. (a) IRF-1 binding to whole or half fragments of the SLPI promoter. Twenty-®ve ng of recombinant IRF-1 protein was incubated with 32 P-labeled probes corresponding to either the entire SLPI promoter (7276 to +1; lanes 1 and 2), the 5' 207 bp of the SLPI promoter (7276 to 769 or SLPI-H/E; lanes 3 and 4), the 3' 69 bp of the SLPI promoter (768 to +1 or SLPI-E/A; lanes 5 and 6) or BS12, a combination of the BS1 and BS2 sites (789 to 745; lanes 7 and 8). To con®rm speci®city of binding, IRF-1 protein was preincubated with 1 ml of anti-IRF-1 antisera (lanes 2, 4, 6 and 8) prior to addition of radiolabeled probe. The arrows indicate the IRF-1 speci®c complexes in lanes 1, 3, and 5, respectively. (b) Localization of IRF-1 binding between nt 7221 to 7200 by DNase I footprinting. An adenine-guanine (A+G) sequence of (+)-sense 32 P-end-labeled SLPI promoter DNA is used as a DNA ladder (lane 1). In the footprint reactions, (+)-sense 32 P-end-labeled SLPI promoter DNA was incubated in the presence of DNA binding buer and 0 ± 100 ng of recombinant IRF-1 protein (lanes 2 ± 6), followed by the addition of DNase I. The sequence of the SLPI promoter between 7200 and 7221 is shown. A DNase I-protected region representing potential IRF-1 binding is depicted on the right. (c) Binding of IRF-1 and IRF-2 protein to F1A and DF1A. 0.125 ± 1.25 ng of IRF-1 (lanes 1 ± 3) or 1 ± 4 ng of IRF-2 (lanes 5 ± 7) recombinant protein was incubated with a 32 P-labeled probe corresponding to F1A (nt 7221 to 7200 on the SLPI promoter). Speci®city of binding was con®rmed by preincubation of IRF-1 protein with 1 ml of anti-IRF-1 antisera (lane 4) prior to addition of radiolabeled probe. Comparable amounts of IRF protein were also incubated with 32 P-labeled DF1A probe, in which the three thymidine residues at nt 7211 to 7209 had been changed to adenines
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RelA. Furthermore, IRF-2 DNA binding to the IRF-2-speci®c Th probe was only detected in whole cell extracts from uninduced cells, as con®rmed by supershift analysis using an IRF-2-speci®c antibody ( Figure  6b, lanes 1, 8 and 10 ). IRF-1/RelA DNA binding activity was not detected in the absence of Dox ( Figure  6b , lane 7) but after Dox induction for 48 and 72 h ± when SLPI expression is completely suppressed (Figure  1b ) ± IRF-1/RelA strongly bound to Th (Figure 6b , lanes 2 to 6 and lane 9). These results, together with the ®nding that IRF-2 does not bind to the SLPI promoter, indicate that IRF-2 does not play a direct role in IRF-1-mediated downregulation of SLPI expression.
Analysis of hSLPI-CAT promoter activity
To examine the potential role of IRFs and NF-kB on transcriptional regulation of SLPI expression, a CAT reporter construct driven by the human SLPI (hSLPI) promoter was analysed in transient transfection studies together with the CMV-IRF-1 plasmid, or transfected with CMV BL empty vector DNA and subsequently treated with eector molecules or infected with Sendai virus (Figure 7 ). Co-transfection with increasing amounts of IRF-1 resulted in a dose-dependent decrease in CAT activity (up to 3.8-fold). Tenfold lower amounts of IRF-1 did not activate the SLPI promoter; it is possible that constitutive, rather than inducible expression of even low amounts of IRF-1 occuring during a transient transfection assay resulted in repression of SLPI expression. Surprisingly, treatment of cells with the IFNg, LPS, dsRNA or Sendai virus infection did not aect hSLPI-CAT activity.
Discussion
The combination of tetracycline inducible transgene expression and dierential display/RNA ®ngerprinting were used to identify the secretory leukocyte protease inhibitor (SLPI) as a novel IRF-1-regulated gene. Characterization of the role of IRF-1 in the regulation of SLPI expression demonstrated that: (1) SLPI mRNA expression was activated early (2 ± 4 h) and then later repressed (12 ± 48 h) following Dox induction of IRF-1/RelA, mediated via two putative IRF-1 sites Repression of SLPI promoter activity in response to IRF-1 co-expression. NIH3T3 cells were either cotransfected with 5 mg of hSLPI-CAT DNA and 15 mg of CMV BL empty vector DNA (considered as 100% relative CAT activity) or cotransfected with 2, 5 or 10 mg of CMV-IRF-1 expression plasmid. In some experiments, cells were treated with either 100 mg/ml IFNg and/or 10 ng/ml LPS, 25 mg/ml dsRNA or infected with 60 hemagglutinating units/ml of Sendai virus 24 h post transfection for a period of 16 ± 24 h. All transfections were performed 3 ± 5 times. CAT activity was assayed using 5 mg of total protein extract for 1 h at 378C
IRF-1 regulation of SLPI expression H Nguyen et al in the SLPI promoter; (2) dsRNA induced expression of SLPI, and expression of IRF-1 or IRF-1/RelA repressed dsRNA-mediated induction of SLPI; (3) an IRF-1 binding site was identi®ed in the 7221 to 7200 region of the SLPI promoter; and (4) SLPI transcription was negatively regulated by IRF-1 in coexpression assays. SLPI plays a primary role in the regulation of neutrophil-mediated in¯ammation through proteolysis and subsequent inhibition of the leukocyte serine proteases, including the neutrophil proteases (cathepsin G and elastase) and the pancreatic proteases (trypsin and chymotrypsin) (Thompson and Ohlsson, 1986) . Because of its potent antiprotease activity, SLPI serves as a potential therapeutic agent for the treatment of proteolytic tissue damage seen in degenerative and in¯ammatory diseases such as cystic ®brosis, allergic rhinitis and asthma (Lee et al., 1993) ; reviewed in Vogelmeier et al. (1996) . This nonglycosylated 11.7 kDa enzyme is produced by epithelial cells and resides in parotid secretions, bronchial, nasal and cervical mucus, and seminal¯uid (Thompson and Ohlsson, 1986) . The relatively high basal levels of SLPI mRNA in ®broblast NIH3T3 cells observed in our experiments is consistent with high production of SLPI by epithelial cells. Phorbol 12-myristate 13-acetate (PMA) and tumor necrosis factor-alpha (TNFa) treatment increases SLPI levels in bronchial epithelial cells (Maruyama et al., 1994; Sallenave et al., 1994) . Activation of SLPI expression by these in¯ammatory stimuli is concordant with its role in in¯ammation. SLPI mRNA levels were also upregulated in response to dsRNA and Sendai virus infection (data not shown), suggesting a potential involvement of SLPI in antiviral defense as well as pathogen response. It would be of interest to determine whether this induction is mediated through dsRNA mediated activation of the dsRNA activated protein kinase PKR (Clemens and Elia, 1997).
Recently, a novel function was assigned to SLPI with its characterization as a macrophage derived inhibitor of macrophage response to LPS (Jin et al., 1997) . SLPI in this context was identi®ed by dierential display as a gene that was overexpressed in primary macrophages from LPS hyporesponsive (Lps d ) C3H/ HeJ mice. Although activated by LPS, SLPI antagonized the LPS response when overexpressed in macrophages (Jin et al., 1997) . One of the components of the LPS pathway inhibited by SLPI was the production of nitric oxide (NO), a major constituent of macrophage cytotoxicity for bacteria and other foreign particles (reviewed in Nathan and Hibbs, 1991) and an agent of antiviral defense (Croen, 1993; Karupiah et al., 1993) . Interestingly, studies in macrophages from IRF knockout mice revealed an essential role for IRF-1 in the transcriptional induction of the nitric oxide synthase gene (iNOS) in macrophages Martin et al., 1994) . Macrophages from IRF-1 de®cient mice produced little or no nitric oxide and synthesized low levels of iNOS mRNA in response to IFNg stimulation. Furthermore, IRF-1 knockout mice were more severely aected by Mycobacterium bovis infection than their wild-type counterparts . The role of IRF-1 in the IFN-g induced activation of iNOS expression is further supported by the presence of two adjacent IRF-1 response elements in the iNOS promoter Martin et al., 1994) . These above observations are consistent with the role of IRF-1 described in the present study, as a repressor of SLPI expression which in turn interferes with NO production.
The RNA ®ngerprint leading to the identi®cation of SLPI, the patterns of SLPI expression late after induction of IRF-1/RelA, and the co-transfection studies all reveal a unique involvement of IRF-1 in repression of SLPI gene transcription. A similar phenomenon was observed previously with IRF-2. Although viewed as a transcriptional repressor, two reports demonstrated that IRF-2 also acts as an activator. Human histone H4 gene FO108 was found to be directly activated by IRF-2 through binding to a cell-cycle element (CCE) present in the H4 promoter (Vaughan et al., 1995) . The Qp promoter region of the Epstein-Barr Virus (EBV)-encoded EBNA-1 gene was also activated by IRF-2 (Nonkwello et al., 1997) . From our studies, IRF-1 repression of SLPI occurs when IRF-1 levels are high. Dox-induced levels of IRF-1 and IRF-1/RelA in the cell inhibited dsRNA-mediated induction of SLPI; interestingly, LPS-mediated SLPI induction was also suppressed by IRF-1 fusion protein expression (data not shown). It is possible that cells which are`primed' by IRF-1 expression are refractory to inducers of SLPI expression as a mechanism of maintaining the pathogen or antiviral response.
Consistent with the direct role of IRF-1 in SLPI regulation, two regions of the SLPI promoter (7221 to 7200 and 751 to 722) were identi®ed that bind IRF-1; in vitro footprinting and EMSA analysis determined the 7200 site as the major site for IRF-1-DNA complex formation. IRF-1 had about tenfold higher anity for the 7221 to 7200 region than the downstream 751 to 722 element, concordant with the fact that the single 5'-GAAA-3' stretch in the downstream sequence represents a half site for IRF-1 binding. It is possible that IRF-1 may bind the 751 to 722 region but only in association with an induced partner' protein. DNA binding of IRF-1 and IRF-2 was previously shown to be enhanced by interaction with the TFIIB component of the basal transcription machinery (Wang et al., 1996) . The proximity of the 751 to 722 IRF-1 site to the TATA box suggest that TFIIB may be a putative candidate as the IRF-1 partner' protein.
Based on available evidence and data presented in this paper, the following model of SLPI regulation is proposed (Figure 8 ). Response to LPS involves the induction of expression of TNFa and nitric oxide as well as the activation of NF-kB transcription factors. LPS also activates expression of SLPI (Jin et al., 1997) . NF-kB may mediate LPS-induced activation of SLPI expression (+) or regulate the LPS response by suppressing SLPI expression (7). IFNg and dsRNA/ Sendai virus infection also activate SLPI expression. Since IRF-1 protein expression correlates with SLPI mRNA expression in IFNg and dsRNA/Sendai virus infected cells (data not shown), IRF-1 serves as a potential mediator of SLPI activation in response to these stimuli. On the other hand, high levels of IRF-1 may trigger a feedback mechanism to regulate SLPI transcription, resulting in suppression of induction by dsRNA and perhaps other SLPI inducers. IRF-1 may repress directly by binding to the IRF-1 binding site(s) in the SLPI promoter and blocking transcription, in which case IRF-1 would be assigned a novel repressor function distinct from its well characterized role as a transcriptional activator (reviewed in Nguyen et al., 1997a) . In contrast, IRF-1 may also function by an indirect mechanism through activation of an unde®ned repressor (X) which would bind directly to the SLPI promoter and repress transcription. Another possibility is that IRF-1 may indirectly alter the stability of SLPI mRNA. Our identi®cation of SLPI as a novel IRF-1 regulated gene and characterization of SLPI gene expression illustrate an interesting but complex mechanism of control, with implications for inflammatory response to viral pathogens.
Materials and methods
RNA ®ngerprinting
The RNA ®ngerprinting reactions were performed using the Delta TM RNA Fingerprinting Kit (CLONTECH Laboratories, Inc.). The reactions were resolved on a 5% Long Ranger TM gel (50% Concentrate; JT Baker, Inc.) in 0.66 TBE. After running at 65 W for 1.5 h, the gel was dried and exposed to Kodak ®lm at 7708C overnight. Bands of interest were removed and reampli®ed, and then subcloned into a Bluescript KS vector containing overhang thymidine (T) bases inserted at the EcoRV site in the multiple cloning region.
RNA extraction and Northern blot analysis
Total cellular RNA was isolated by the guanidium thiocyanate method as described in Chomczynski and Sacchi (1987) . Ten to twenty mg of total RNA was denatured, electrophoresed in a denaturing formaldehyde/1.2% agarose gel, and transferred to nylon membrane. IRF-1/RelA and SLPI mRNA were visualized by Northern blot hybridization using the ®rst 300 bp of the IRF-1 cDNA or a 400 bp fragment of SLPI cDNA (nucleotides 786 ± 1089), respectively, labeled with a-32 P-dCTP by nick translation using the Oligolabelling Kit (Pharmacia Biotech).
Electrophoretic mobility shift assays
Whole cell extracts for analysis of DNA binding were prepared as described in (Cohen et al., 1991) . Twenty micrograms (20 mg) of whole cell extract or one to ten nanograms (1 ± 10 ng) of recombinant protein were preincubated for 10 min at room temperature in the presence of binding buer (10 mM: Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 5% glycerol, 0.5% Nonidet P-40, and 62.5 mg/ml of the non-speci®c DNA competitor poly (dIdC) (Pharmacia Biotech) in a total volume of 20 ml. Reaction mixtures involving the recombinant proteins also contained 10 mg/ml bovine serum albumin. Following 30 min of incubation with 75 000 c.p.m. of labeled probe at room temperature, the mixtures were loaded on a 5% polyacrylamide gel (60:1 cross-link) prepared in 0.56TBE. After running at 200 V for 2.5 h, the gel was dried and exposed to Kodak ®lm at 7708C overnight. To test the speci®city of DNA binding, recombinant protein or whole cell extract from cells treated with 100 units/ml IFNg (Sigma) for 0 ± 18 h was pre-incubated with antiserum or 500-fold excess of unradiolabeled competitor DNA for 10 min at room temperature in binding buer, prior to the addition of probe. The sequence of the probes used are as follows: Th (synthetic tetrahexamer of minimal IRF binding site): 5'-(AAGTGA) 4 -3'; BS1 (nt 789 to 761 of the SLPI promoter): 5'-AGCTGGGAGAGGCCCGAAAGAATTCTGGT-3'; BS2 (nt 779 to 745 of the SLPI promoter): 5'-GCCCGAAA-GAATTCTGGTGGGGCCCACCCA CTG-3'; BS12 (nt 789 to 745 of the SLPI promoter (BS1 and BS2 combined)): 5'-AGCTGGGAGAGGCCCGAAAGAATTC-TGGTGGGGCCACACCCACTG-3'; SLPI-H/E: nt 7276 to 769 of the SLPI promoter; SLPI-E/A: nt 768 to +1 of the SLPI promoter; F1A (nt 7224 to 7201 of the SLPI promoter): 5'-CCAATCTCTTCCCTTTCTTTTCTC-3'; DF1A (point-mutated SLPI-F1A): 5'-CCAATCTCTTCCC-AAACTTTTCTC-3'; and F1B (nt 751 to 722 of the SLPI promoter).
Western blot analysis
Twenty mg of whole cell extract was subject to SDSpolyacrylamide gel electrophoresis (SDS ± PAGE) in a 10% polyacrylamide gel. After electrophoresis, the proteins were transferred to Hybond transfer membrane (Amersham) in a buer containing 30 mM Tris, 200 mM glycine and 20% methanol for 1 h. The membrane was blocked by incubation in phosphate-buered saline (PBS) containing 5% dried milk for 1 h and then probed with IRF-2 (Santa Cruz Biotechnology, Inc.) or C-terminal NF-kB RelA (Pepin et al., 1994) antibody in 5% milk/PBS, at a dilution of 1 : 1000. These incubations were done at 48C overnight or at room temperature for 1 ± 3 h. After four 10 min washes with PBS, membranes were reacted with a peroxidase-conjugated secondary goat anti-rabbit or anti-mouse antibody (Amersham) at a dilution of 1 : 2500. The reaction was then visualized with the enhanced chemiluminescence detection system (ECL) as recommended by the manufacturer (Amersham Corp.).
Transient transfection and reporter gene assay
Transient transfections were carried out in murine NIH3T3 cells grown in Dulbecco's Modi®ed Eagles Medium (DMEM) supplemented with 10% fetal bovine serum, glutamine and antibiotics. Subcon¯uent cells were transfected with CsCl puri®ed chloramphenicol acetyltransferase (CAT) reporter driven by the human SLPI promoter (hSLPI-CAT) and CMV-IRF-1 expression plasmid by lipofection (Lipofectamine, Life Technologies, Inc.) according to manufacturer's instructions. In some experiments, cells were treated with either 100 units/ml IFNg (Sigma), 10 mg/ml LPS (Sigma), both IFNg and LPS, or 25 mg/ml poly (I):poly (C), or infected with Sendai virus (60 hemagglutinating units/ml for 90 min) 24 h post transfection for a period of 16 ± 24 h. All transfections were performed 3 ± 5 times. CAT activity was assayed using 5 mg of total protein extract for 1 h at 378C.
DNAseI footprinting
For DNAseI footprinting of the sense (+) strand, a HindIII/ AccI fragment encompassing the complete known promoter region (nucleotides 7276 to +1 of the SLPI gene) was endlabeled at the HindIII site. An adenine-guanine (A+G) DNA ladder was formed with 10 000 ± 20 000 c.p.m. of probe using the chemical (Maxam-Gilbert) sequencing method. The reaction was then completed by the addition of hydrazine stop solution (0.3 M sodium acetate, pH 7.0; 0.1 mM EDTA, pH 8.0; and 100 mg/ml yeast tRNA), ethanol precipitated and then resuspended in 6 ml of formamide loading buer (90% formamide, 10% bromophenol blue and 10% xylene cyanol).
The footprinting reactions were performed as described in Lin et al., (1992) . Essentially, end-labeled DNA was incubated in the presence of DNA binding buer containing 10 mg/ml BSA and 0 to 150 ng of polyhistidine-tagged recombinant IRF-1 protein. After 10 min at room temperature, DNaseI was added and the reaction was incubated for 2 min at 308C. The reaction was then terminated by the addition of stop solution (0.6 M sodium acetate, pH 5.2, 50 mM EDTA and 1.5 mg/ml salmon sperm DNA). Protein was removed by phenol-chloroform extraction and the resulting DNA was precipitated and resuspended in 6 ml of formamide loading buer. The DNA ladder and footprinting reactions were then electrophoresed on a 5% polyacrylamide (19 : 1 crosslink)-8 M urea sequencing gel. After running at 65 W for 1.5 h, the gel was dried and exposed to Kodak ®lm at 7708C overnight.
